Product Center
Launch Ceremony of Tetravalent Influenza Virus Subunit Vaccine Huierkangxin Successfully Held!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26
- Views:
(Summary description)On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
Launch Ceremony of Tetravalent Influenza Virus Subunit Vaccine Huierkangxin Successfully Held!
(Summary description)On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26 10:00
- Views:
On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
At the ceremony, Mr. An Youcai, Chairman and General Manager, reflected on eight years of hard work, acknowledged the team’s achievements, and shared his vision for the future. He emphasized that "only through innovation can we go far" and urged the team to stay committed to the five-year strategic goals, strive for progress, and jointly build a stronger line of defense for global health.
The official launch of Huierkangxin will provide society with a more advanced, safer, and more effective influenza vaccination option, reduce vaccine hesitancy, further increase the influenza vaccination rate, and contribute to China’s influenza prevention and control efforts.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
